Home Featured Page 232

Featured

Latest

The Psychedelic News Feed: January 26 – Febraury 1, 2026

Q3 2025: Oregon Psilocybin Services Update

Patient Safety After a Death: What Transparency Can and Cannot Do

January 2026 Psychedelic Bill Round-up

The Psychedelic News Feed: January 19 – 25, 2025

Small Pharma Announces Appointment of Lyne Fortin as Chair of the...

PTSF74 – A Response: Decriminalize Nature, SB-519, and MAPS

Filament Health Successfully Completes Industry-first Export of Natural GMP Psychedelics to...

Scientists Isolate Two New Compounds from Toad Venom

Psilera Collaborates with the National Institute on Drug Abuse (NIDA) to...

Mindset Pharma Announces Preclinical Results Demonstrating Extended Duration of Action in...

MYND Life Sciences Announces $3 Million Convertible Debenture Unit Offering

MINDCURE Reaches Milestone, Releasing First of its Kind Mental Health Digital...

Silo Pharma Advances Psychedelic Patent Portfolio

PharmaDrug Announces Clinical Research Collaboration with The Johns Hopkins University to...

1...231232233...307 Page 232 of 307

EDITOR PICKS

The Psychedelic News Feed: January 26 – Febraury 1, 2026

Q3 2025: Oregon Psilocybin Services Update

Patient Safety After a Death: What Transparency Can and Cannot Do

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

The Psychedelic News Feed: January 26 – Febraury 1, 2026

Q3 2025: Oregon Psilocybin Services Update

Patient Safety After a Death: What Transparency Can and Cannot Do

January 2026 Psychedelic Bill Round-up

The Psychedelic News Feed: January 19 – 25, 2025

Small Pharma Announces Appointment of Lyne Fortin as Chair of the...

PTSF74 – A Response: Decriminalize Nature, SB-519, and MAPS

Filament Health Successfully Completes Industry-first Export of Natural GMP Psychedelics to...

Scientists Isolate Two New Compounds from Toad Venom

Psilera Collaborates with the National Institute on Drug Abuse (NIDA) to...

Mindset Pharma Announces Preclinical Results Demonstrating Extended Duration of Action in...

MYND Life Sciences Announces $3 Million Convertible Debenture Unit Offering

MINDCURE Reaches Milestone, Releasing First of its Kind Mental Health Digital...

Silo Pharma Advances Psychedelic Patent Portfolio

PharmaDrug Announces Clinical Research Collaboration with The Johns Hopkins University to...

EDITOR PICKS

The Psychedelic News Feed: January 26 – Febraury 1, 2026

Q3 2025: Oregon Psilocybin Services Update

Patient Safety After a Death: What Transparency Can and Cannot Do

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY